pms-Sumatriptan

Sumatriptan succinate

Acute treatment of migraine attacks w/ or w/o aura.

Adult 25-100 mg single dose. Max recommended single dose: 100 mg. If migraine headache returns or in case of partial response to the initial dose, dose may be repeated after 2 hr. Not more than 200 mg should be taken in any 24-hr period.

May be taken with or without food.

Hypersensitivity. Patients w/ history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes, valvular heart disease or cardiac arrhythmias (especially tachycardias); other significant underlying CV diseases (eg, atherosclerotic disease, congenital heart disease); uncontrolled or severe HTN; hemiplegic, basilar, or ophthalmoplegic migraine. Concurrent administration of MAOI or use w/in 2 wk of discontinuation of MAOI therapy. Use w/in 24 hr before or after treatment w/ other 5-HT₁ receptor agonists, or ergotamine-containing drugs or their derivatives (eg, dihydroergotamine, methysergide). Should not be administered to patients w/ severe hepatic impairment.

Not intended for the prophylactic therapy of migraine. Should only be used where a clear diagnosis of migraine has been established. Inapplicable for cluster headache. Risk of exacerbation of headache w/ overuse of acute headache treatments. Risk of myocardial ischemia &/or infarction & other adverse cardiac events. Should not be used in patients w/ history of hypersensitivity to multiple allergens or to chemically related 5-HT₁ receptor agonists. Exclude other potentially serious neurologic conditions before treating headache in patients not previously diagnosed w/ migraine headache or who experience a headache that is atypical for them. Possibility of long-term ophthalmologic effects. Drowsiness may occur. Concomitant use w/ SSRIs/serotonin norepinephrine reuptake inhibitors (SNRIs). Caution in patients w/ a history of seizures or other risk factors eg, structural brain lesions. Consider 25-mg oral dose in patients w/ mild or moderate hepatic impairment. Not recommended in patients w/ renal impairment. Pregnancy & lactation. Not recommended in childn <18 yr & elderly >65 yr.

Sensations of heaviness, pressure, tightness or pain.

Additive prolongation of vasospastic reactions w/ ergot-containing or ergot-type medications (eg, dihydroergotamine or methysergide). Increased systemic exposure w/ MAOIs. Serotonin syndrome w/ SSRIs/SNRIs. Potential increased risk of coronary vasospasm w/ other 5-HT₁ agonists.

Antimigraine Preparations

N02CC01 - sumatriptan ; Belongs to the class of selective serotonin (5HT1) agonists preparations. Used to relieve migraine.

P₁S₁S₃